Clear cell/endometrioid type ovarian carcinoma associated with endometriosis of the ipsilateral ovary

Ivana Rudić Biljić-Erski; Mladenko Vasiljević; Snežana Rakić; Olivera Džatić-Smiljković; Sladjana Mihajlovic

doi:10.2298/VSP170424107R

Ivana Rudić Biljić-Erski Clinic of Gynecology and Obstetrics “Narodni Front”, Belgrade, Serbia
Mladenko Vasiljević Clinic of Gynecology and Obstetrics “Narodni Front”, Belgrade, Serbia
Snežana Rakić Clinic of Gynecology and Obstetrics „Narodni Front“, Belgrade, Serbia
Olivera Džatić-Smiljković Clinic of Gynecology and Obstetrics „Narodni Front“, Belgrade, Serbia
Sladjana Mihajlovic Clinic of Gynecology and Obstetrics „Narodni Front“, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP170424107R

Keywords: adenocarcinoma, clear cell;, diagnosis;, endometriosis;, ovarian neoplasms;, treatment outcome.

Abstract

Introduction. Ovarian endometriosis has been identified as a risk factor for occurrence of endometriosis-associated ovarian carcinoma. We presented a rare case of simultaneous clear cell/ endometrioid ovarian carcinoma and endometriosis of the ipsilateral ovary. Case report. A 47-year- old patient underwent surgery for right ovarian endometriotic cyst. A total hysterectomy with bilateral salpingo-oophorectomy, lymphadenectomy in the right psoas muscle region and omentectomy were performed as well as multiple peritoneal biopsies. Six cycles of chemotherapy were instituted postoperatively using the Taxol-CBDCA protocol. Abdominal and pelvic CT did not demonstrate recurrence of the disease postoperatively and after completed chemotherapy treatment. Six months after the completion of treatment, the patient felt well without the disease recurrence. Conclusion. Clear cell and endometrioid subtypes of ovarian carcinoma have good prognosis if they are diagnosed and treated at an early stage of the disease. In our patient, the carcinoma was detected in the first stage and successfully treated with combination therapy, i.e., surgical and chemotherapy.

References

Lyttle B, Bernardi L, Pavone ME. Ovarian cancer in endometri-osis: Clinical and molecular aspects. Minerva Ginekol 2014; 66(2): 155‒64.

Forte A, Cipollaro M, Galderisi U. Genetic, epigenetic and stem cell alterations in endometriosis: New insights and potential therapeutic perspectives. Clin Sci 2014; 126(2): 123‒38.

Pavone ME, Lyttle BM. Endometriosis and ovarian cancer: Links, risks, and challenges faced. Int J Womens Health 2015; 7: 663‒72.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69‒90.

Wang S, Qiu L, Lang JH, Shen K, Yang JK, Huang MF, et al. Clinical analysis of ovarian epithelial carcinoma with coexist-ing pelvic endometriosis. Am J Obstet Gynecol 2013; 208: 413.e1–413.e5.

Burghaus S, Häberle L, Schrauder M, Heusinger K, Thiel F, Hein A, et al. Endometriosis as a risk factor for ovarian or endome-trial cancer-results of a hospital-based case control study. BMC Cancer 2015; 15: 751.

Noli S, Cipriani S, Scarfone G, Villa A, Grossi E, Monti E, et al. Long term survival of ovarian endometriosis associated clear cell and endometrioid ovarian cancers. International journal of gynecological cancer 2013; 23(2): 244‒8.

Ma X, Hui Y, Lin L, Wu Y, Zhang X, Qin X. Possible rele-vance of tumor-related genes mutation to malignant transfor-mation of endometriosis. Eur J Gynaecol Oncol 2016; 37(1): 89‒94.

Suryawanshi S, Huang X, Elishaev E, Budiu RA, Zhang L, Kim S, et al. Complement pathway is frequently altered in endome-triosis and endometriosis-associated ovarian cancer. Clin Can-cer Res 2014; 20(23): 6163‒74.

Borrelli GM, Abrão MS, Taube ET, Darb-Esfahani S, Köhler C, Chiantera V, et al. (Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes. Mol Hum Reprod 2016; 22(5): 329‒37.

Rechsteiner M, Zimmermann A, Wild PJ, Caduff R, Teichman A, Fink D, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol 2013; 95(2): 235‒41.

Worley MJ, Liu S, Hua Y, Kwok JS, Samuel A, Hou L, et al. Mo-lecular changes in endometriosis-associated ovarian clear cell carcinoma. Eur J Cancer 2015; 51(13): 1831‒42.

Helder-Woolderink JM, Blok EA, Vasen HFA, Hollema H, Mour-its MJ, De De Bock GH. Ovarian cancer in Lynch syndrome: as systematic review. Eur J Cancer 2016; 55: 65-73.

Teixeira N, Mourits MJ, Vos JR, Kolk DM, Jansen L, Oosterwijk JC, et al. Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk. Maturitas 2015; 82(2): 197‒202.